A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer
progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study
will test the safety and effects of the combination ADH-1 and carboplatin or ADH-1 and
docetaxel or ADH-1 and capecitabine in subjects with specific incurable, solid tumors with a
protein biomarker called N-cadherin.